MAPK1 and prostate cancer: GPR30/ERK signaling activation leads to block of proliferation in androgen-independent PC3 prostate cancer cells [32], whereas G-1 agonist causes cell cycle arrest in HEK-293 and MDA-MB231 breast cancer GPER-negative cells and in KGN ovarian cancer cells siRNA knockdown of GPER [37].